GRI Bio, Inc. (NASDAQ:GRI) Short Interest Update

GRI Bio, Inc. (NASDAQ:GRI) was the recipient of a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 383,633 shares, an increase of 169.5% from the November 30th total of 142,328 shares. Based on an average daily volume of 2,103,519 shares, the days-to-cover ratio is presently 0.2 days. Approximately 11.8% of the shares of the company are short sold. Approximately 11.8% of the shares of the company are short sold. Based on an average daily volume of 2,103,519 shares, the days-to-cover ratio is presently 0.2 days.

GRI Bio Trading Down 10.2%

GRI traded down $0.03 on Friday, hitting $0.29. 1,262,596 shares of the company’s stock were exchanged, compared to its average volume of 605,049. GRI Bio has a fifty-two week low of $0.29 and a fifty-two week high of $15.64. The stock has a market cap of $948,010.00, a price-to-earnings ratio of -0.03 and a beta of -1.48. The firm has a 50-day moving average price of $1.53 and a 200-day moving average price of $1.59.

GRI Bio (NASDAQ:GRI) last posted its quarterly earnings results on Friday, November 14th. The company reported ($1.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.17). On average, equities analysts predict that GRI Bio will post -3.04 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on GRI. Weiss Ratings reiterated a “sell (e+)” rating on shares of GRI Bio in a report on Wednesday, October 8th. Ascendiant Capital Markets upped their price objective on shares of GRI Bio from $35.00 to $36.00 and gave the company a “buy” rating in a report on Monday, December 8th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, GRI Bio has a consensus rating of “Hold” and a consensus target price of $23.00.

GRI Bio Company Profile

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.